Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. - Wikidata - awgldk - TriplyDB

Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

http://www.wikidata.org/entity/Q42947899

about

DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies.Rhabdomyosarcomas in aging A/J mice.Myostatin is elevated in congenital heart disease and after mechanical unloading Dystrophin is a tumor suppressor in human cancers with myogenic programs.MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line.Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice Advances in pediatric rhabdomyosarcoma characterization and disease model development.Cancer-related genes in the transcription signature of facioscapulohumeral dystrophy myoblasts and myotubes.Rhabdomyosarcomas: an overview on the experimental animal models.Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome.Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma.Dystroglycan function is a novel determinant of tumor growth and behavior in prostate cancer.ABC of multifaceted dystrophin glycoprotein complex (DGC).Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens?Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer.A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.Increased FSHD region gene1 expression reduces in vitro cell migration, invasion, and angiogenesis, ex vivo supported by reduced expression in tumors.The human, F-actin-based cytoskeleton as a mutagen sensor.Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir.Facioscapulohumeral dystrophy myoblasts efficiently repair moderate levels of oxidative DNA damage.

P2860

Q33886594-F29B742D-6150-4F41-9D74-644DABC38A96 Q33997217-7231E9FD-3254-4833-8900-5638FDF62B42 Q34023157-22119391-2AB3-4010-AE4A-AAAEDEE39A30 Q34479070-D9C988EE-3F46-4C4E-81D2-A5E6AAFD2E9A Q35667137-243223A9-0385-4C42-9C4F-0AA86E32B14B Q36025454-4DB827FC-49C4-4160-A382-046F1A84F48E Q36142754-5ADDA9B6-AF5C-4CDF-86EC-9847CE94AAE2 Q36167600-67D53D1A-E307-441C-929C-6F3798D19D71 Q36503375-D10FC580-0BEF-4C59-A406-B5B816F3256E Q37580831-1A5FAE72-0061-41EF-B52C-1C31AE8E8D0E Q37595289-2C7F7721-450C-420C-9102-FBC73ECC1139 Q37973827-499A54A7-A4D2-4681-B4F3-F89A236F7543 Q38105879-D0FCAE56-34FD-4881-8F1F-9BB36961C6E8 Q38703661-360FB4CC-B937-482D-819E-4CA55C4FEA47 Q38893243-DBC6BAF1-3CCB-4846-B374-F786F04D4D1C Q39274601-81E56BB1-6844-4AFC-8E8A-5F7721A7D92F Q39278570-5D2E6B46-8E1B-4124-BFD7-C35803673A9F Q40678653-3036FAB3-F7D6-4F9A-970C-FC5A2B4C07C7 Q41116449-776250BA-F279-4389-96F1-997E5F86D88E Q46456978-B75554B5-70EF-418B-AF8A-834A00223192 Q47119855-A04C349F-C457-4B0C-9BF0-A4ADBC3CBFC3 Q47162190-EA171908-ED78-426F-8B55-CDA02CEF6A5A Q47630972-8C513A5C-50A3-4538-BF3D-9BCC0FCC031F Q48243281-FD121E45-457C-42BB-8A91-D8BE7D33ED74

P2860

Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

http://www.wikidata.org/entity/Q42947899

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Mice lacking dystrophin or alp ...... ed or mutant Mdm2 transcripts.

@en

Mice lacking dystrophin or alp ...... ed or mutant Mdm2 transcripts.

@nl

type

label

Mice lacking dystrophin or alp ...... ed or mutant Mdm2 transcripts.

@en

Mice lacking dystrophin or alp ...... ed or mutant Mdm2 transcripts.

@nl

prefLabel

Mice lacking dystrophin or alp ...... ed or mutant Mdm2 transcripts.

@en

Mice lacking dystrophin or alp ...... ed or mutant Mdm2 transcripts.

@nl

P1433

Q42947899-DBAFA4B4-1537-4726-AB67-D132F3C8E241

P1476

Q42947899-2AE137C6-BEFB-49D3-941C-3F07D1BE1B41

P2093

Q42947899-0AD9650C-6838-4511-848B-2C3D7027F0C5

Q42947899-0B051BC9-DE7E-4A56-BEC3-07A64F4BC13F

Q42947899-1939DDCE-0011-4FC9-963B-D95DD355E9AE

Q42947899-24FA441B-FADC-43AB-81BB-4D9BA4DCABD8

Q42947899-B3A94C18-61FD-4781-821E-9EEEB01B8F70

P2860

Q42947899-00E1FD64-7720-479E-925A-B7D69275508F

Q42947899-01AC67F9-B194-4C5B-AB4E-E6FFB02576C2

Q42947899-01DC506E-9089-4769-9F55-47B9E87357B8

Q42947899-05E202B1-D312-4110-AE50-6D19D562D8AE

Q42947899-0A375DEF-3A4E-439A-B673-7068CC9C852C

Q42947899-0C531263-DA22-44F1-BE22-20657B874973

Q42947899-1125F804-A425-4B5A-BE8B-44FCCCA0D5F2

Q42947899-11B1316B-F032-4196-8826-AB16A45913AD

Q42947899-122DA6B1-086A-4259-A7E2-84611289C1E4

Q42947899-14E96D03-49C2-40F6-B820-528A55897718

P304

Q42947899-C529E4B3-F871-4CC4-9B36-F9FB32F26D04

P31

Q42947899-68CDA61D-E930-4C0A-A65A-82332624DB42

P356

Q42947899-0874EE6B-7819-483A-83DB-671299167DDA

P407

Q42947899-C4C91072-0D75-41BC-8DF9-54A65776EAD1

P433

Q42947899-2E29DDCE-31F2-4EB4-B130-23321B2F40F2

P478

Q42947899-9A87DC0F-B9B5-475E-8F18-23609B6D7FC3

P577

Q42947899-15637740-B35A-4F33-8900-A4F82A924E85

P5875

Q42947899-AF188266-BE5B-4F0E-8F40-1960550E79AA

P698

Q42947899-0C1778EE-F0EC-494C-BEEF-F2FA145D4B8D

P932

Q42947899-AD9C7410-4051-408C-8A7F-612456E8BB34

P356

AJPATH.2010.090405

P1433

The American Journal of Pathology

P1476

Mice lacking dystrophin or alp ...... ed or mutant Mdm2 transcripts.

@en

P2093

Karen Fernandez

http://www.w3.org/2001/XMLSchema#string

Laura T Martin

http://www.w3.org/2001/XMLSchema#string

Paul T Martin

http://www.w3.org/2001/XMLSchema#string

Sue Hammond

http://www.w3.org/2001/XMLSchema#string

Yelda Serinagaoglu

http://www.w3.org/2001/XMLSchema#string

P2860

Tyrosine phosphorylation of beta-dystroglycan at its WW domain binding motif, PPxY, recruits SH2 domain containing proteins

Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase

Dystroglycan, a scaffold for the ERK-MAP kinase cascade.

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

p53, the cellular gatekeeper for growth and division

PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group

Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex

Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix

The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies

SH3 domain-mediated interaction of dystroglycan and Grb2

P304

416-434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2010.090405

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40696546

http://www.w3.org/2001/XMLSchema#string

P698

20019182

http://www.w3.org/2001/XMLSchema#string

P932

2797901

http://www.w3.org/2001/XMLSchema#string